Germany’s lawmakers approved an act that will increase rebates on sales of patented drugs, with the rebate rate rising from 7% to 15.5%. The policy also sets a 9% rebate on patented vaccines and includes price freezes through 2030 paired with price-volume controls intended to restrict overall spending. The move is expected to tighten financial conditions for branded therapy revenues and could influence pricing and contract negotiations across the European market. Separately, CMS proposed changes affecting remote patient monitoring reimbursement: the rulemaking would bar Medicare payment for remote monitoring services delivered by third-party vendors under the 2027 Physician Fee Schedule, following OIG reports that flagged widespread fraud concerns in the category. That creates immediate compliance and business-model pressure for companies selling monitoring services to health systems.